Abbott Laboratories(ABT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 5:32 PM ET (Korea 9/11 06:32)
Full metrics table
| Index | S&P 500 | P/E | 33.41 | EPS (ttm) | 3.09 | Insider Own | 0.69% | Shs Outstand | 1.73B | Perf Week | -6.44% |
| Market Cap | 178.85B | Forward P/E | 17.04 | EPS next Y | 9.93% | Insider Trans | -3.17% | Shs Float | 1.72B | Perf Month | -5.8% |
| Enterprise Value | 206.51B | PEG | 1.83 | EPS next Q | 1.42 | Inst Own | 82.12% | Short Float | 1.19% | Perf Quarter | 15.91% |
| Income | 5.41B | P/S | 3.84 | EPS this Y | 7.13% | Inst Trans | -1.37% | Short Ratio | 1.84 | Perf Half Y | -6.25% |
| Sales | 46.59B | P/B | 3.5 | EPS next 5Y | 9.3% | ROA | 5.59% | Short Interest | 20.38M | Perf YTD | -17.5% |
| Book/sh | 29.54 | P/C | 31.92 | EPS past 3/5Y | -1.7% 8.23% | ROE | 10.63% | 52W High | -24.82% ($137.49) | Perf Year | -20.1% |
| Cash/sh | 3.24 | P/FCF | 22.86 | Sales past 3/5Y | 0.51% 5.08% | ROIC | 6.7% | 52W Low | 26.09% ($81.97) | Perf 3Y | 2.61% |
| Dividend Est. | $2.58 (2.49%) | EV/EBITDA | 18.59 | EPS Y/Y TTM | -61.33% | Gross Margin | 52.81% | Volatility(W/M) | 2.81% 2.27% | Perf 5Y | -19.75% |
| Dividend TTM | 2.48 | EV/Sales | 4.43 | Sales Y/Y TTM | 8.06% | Oper. Margin | 16.44% | ATR (14) | 2.73 | Perf 10Y | 152.04% |
| Dividend Ex-Date | 2026/7/15 | Quick Ratio | 0.97 | EPS Q/Q | -48.22% | Profit Margin | 11.6% | RSI (14) | 36.19 | Recom | 1.57 |
| Dividend Gr. 3/5Y | 7.72% 9.42% | Current Ratio | 1.38 | Sales Q/Q | 13.02% | SMA20 | -7% ($111.14) | Beta | 0.58 | Target Price | $120.75 |
| Payout | 64.54% | Debt/Eq | 0.64 | Earnings | 2026/7/16 | SMA50 | -1.66% ($105.1) | Rel Volume | 0.69 | Prev Close | $105.23 |
| Employees | 115000 | LT Debt/Eq | 0.58 | EPS/Sales Surpr. | 2.56% 0.59% | SMA200 | -2.47% ($105.98) | Avg Volume(3M) | 11.08M | Price | $103.36 |
| IPO | 1937/3/1 | Option/Short | Yes/Yes | Trades | 56405 | Volume | 7,646,683 | Change | -1.78% |
Company
ABT is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A global diversified healthcare company operating medical devices, diagnostics, nutrition, and established pharmaceuticals businesses. Founded in 1888 and headquartered in the US, it holds a leading global position in diabetes care, cardiovascular medical devices, and diagnostics.
Over the past 1 year, roughly in the middle
25% below its 1-year high.
ABT earns at a steady pace
16.44% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +7.1% this year.
Tap to view numbers
But it is not cheap
Trading at 33.4 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +2.6% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 2.49% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 82.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IHI 0.17%
PJP 0.04%
TMED 0.04%
CTIF 0.03%
GVLE 0.03%It is the largest in the industry
Based on market cap of $179B.
ABT $179B PER 33.4
MDT $117B PER 22.6
SYK $104B PER 28.0
BSX $62B PER 17.5
FAQ
What kind of company is ABT?
ABT belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of ABT?
The market cap of ABT is approximately $178.9B, ranking 89 within its sector.
Does ABT pay dividends?
ABT has a dividend yield of approximately 2.49%, with an annual dividend of $2.58.
What is the P/E ratio of ABT?
ABT has a P/E ratio of approximately 33.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ABT?
ABT has recorded a 52-week high of $137.49 and a low of $81.97.
